Sanofi gets rated buy today, agreeing with bullish ratings from the Wall Street and SA analysts' consensus. With a diverse ...

However, Paul Hudson, CEO of Sanofi, one of the world's leading biopharmaceutical companies, says executives may need to rein ...

The program taps into several OpenAI models and can be used across a wide range of therapeutic indications. Both Big Pharma ...

Novavax has made a smaller splash in the U.S. Covid-19 vaccine market than it had hoped. But it's betting on licensing deals ...

The drugmaker has won an appeal against NICE's recent final draft guidance on Sarclisa (isatuximab) as a regimen alongside ...

Healx will use its AI-based drug discovery tech to analyze proprietary Sanofi compound data and identify potential rare disease targets.

Yuichi Iwaki, M.D., Ph.D., MediciNova CEO commented, “The successful resolution of the Sanofi-Novartis litigation and the resulting monetary damages due to MediciNova both validates the value of our ...

New Delhi: Reviewing the Phase III clinical trial protocol of the GZ402671 (Venglustat) presented by the pharma major Sanofi, ...

Sanofi has released phase 3 data from the LUNA 3 trial of rilzabrutinib that should spark some buyer’s delight. | Sanofi has released phase 3 data from the LUNA 3 trial of rilzabrutinib that should ...

An eczema drug jointly developed by pharmaceutical companies Regeneron and Sanofi continues to stand above all comers when it ...

Regeneron (REGN) and Sanofi (SNY) announced that the European Commission, or EC, has approved Dupixent to treat eosinophilic esophagitis, or ...

Brad Lightcap, COO, OpenAI "We believe AI can accelerate drug development, bringing new treatments to patients more quickly. This first product from our collaboration with Sanofi and Formation Bio is ...